AC Immune SA (NASDAQ:ACIU - Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.51 and traded as low as $2.87. AC Immune shares last traded at $2.94, with a volume of 79,680 shares.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AC Immune in a report on Friday, November 15th. StockNews.com cut shares of AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st.
View Our Latest Stock Report on ACIU
AC Immune Trading Down 0.3 %
The firm has a market capitalization of $289.89 million, a P/E ratio of -6.39 and a beta of 1.26. The firm has a 50 day moving average price of $3.17 and a 200-day moving average price of $3.49.
Institutional Investors Weigh In On AC Immune
Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Capital Wealth Advisors bought a new position in AC Immune during the 2nd quarter valued at about $56,000. China Universal Asset Management Co. Ltd. grew its stake in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock valued at $72,000 after buying an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of AC Immune in the second quarter worth approximately $218,000. Geode Capital Management LLC lifted its stake in shares of AC Immune by 6.4% during the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock worth $220,000 after acquiring an additional 3,499 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company's stock valued at $1,755,000 after acquiring an additional 328,312 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company's stock.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
